Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bungarus candidus antivenom
- Development stage
- Unknown
- Lead developer
- Queen Saovabha Memorial Institute
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bungarus candidus antivenom is a biologic product consisting of polyclonal antibodies specifically raised against the venom of the Malayan krait (Bungarus candidus), a highly neurotoxic snake found in Southeast Asia. The primary mechanism of action is neutralization of neurotoxins present in B. candidus venom, which are responsible for presynaptic neuromuscular inhibition and potentially fatal paralysis. The main indication is the treatment of systemic envenoming following bites from B. candidus, with early administration shown to reduce hospitalization time and improve clinical outcomes[1][2][3][5]. This monovalent antivenom does not cross-neutralize venoms from other Bungarus species[2][6]. It was developed and is primarily manufactured by the Queen Saovabha Memorial Institute (Thai Red Cross Society) in Thailand, with additional production by Venom Research & Antivenom Production Unit (Vietnam) and related units[5][8].
- Brand names
- BCAV
- Other names
- Malayan krait antivenomBungarus candidus monospecific antivenom
02
Targets
Muscle-type nicotinic acetylcholine receptor
Beyond the preview
Go deeper on Bungarus candidus antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bungarus candidus antivenom.